Prognostic factors in 1,521 melanoma patients with distant metastases - PubMed (original) (raw)
. 1995 Sep;181(3):193-201.
Affiliations
- PMID: 7670677
Prognostic factors in 1,521 melanoma patients with distant metastases
A Barth et al. J Am Coll Surg. 1995 Sep.
Abstract
Background: Although over 7,000 people die from malignant melanoma each year, there are limited prognostic data for patients with metastatic disease. A retrospective analysis was undertaken to identify variables that accurately predict outcome and to determine if the survival rate of patients with melanoma treated for distant metastases (American Joint Committee on Cancer [AJCC] stage IV disease) at the authors' institution changed between 1971 and 1993.
Study design: Data for 1,521 patients with AJCC stage IV melanoma treated by the staff of the John Wayne Cancer Institute were reviewed, and a univariate and multivariate survival analysis against ten clinical and pathological variables was performed using the Cox proportional hazard regression model.
Results: The median survival time of the 1,521 patients was 7.5 months; the estimated five-year survival rate was 6 percent. Three independent variables predicted survival: initial site of metastases (p < 0.0001); disease-free interval before distant metastases (p = 0.0001); and stage of disease preceding distant metastases (p = 0.0001). Patients could be divided into three distinct prognostic groups based on the initial site of metastases: cutaneous, nodal, or gastrointestinal metastases (median survival of 12.5 months; estimated five-year survival rate 14 percent); pulmonary metastases (median survival of 8.3 months; estimated five-year survival rate 4 percent); and metastases to the liver, brain, or bone (median survival of 4.4 months; estimated five-year survival rate 3 percent). There was no significant change in the survival rate of patients with AJCC stage IV melanoma during the 22-year review period.
Conclusions: Despite new treatment options, the survival rate of patients with metastatic melanoma has not changed significantly over the last 22 years; their prognosis remains dismal. The three prognostic variables identified in this study should be considered in the design of future clinical trials.
Comment in
- Prognosis of patients with advanced melanoma.
Eberlein TJ. Eberlein TJ. J Am Coll Surg. 1995 Sep;181(3):263-5. J Am Coll Surg. 1995. PMID: 7670686 No abstract available.
Similar articles
- Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF. Francken AB, et al. Ann Surg Oncol. 2008 May;15(5):1476-84. doi: 10.1245/s10434-007-9717-9. Epub 2008 Jan 15. Ann Surg Oncol. 2008. PMID: 18196345 - Contemporary surgical treatment of advanced-stage melanoma.
Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Essner R, et al. Arch Surg. 2004 Sep;139(9):961-6; discussion 966-7. doi: 10.1001/archsurg.139.9.961. Arch Surg. 2004. PMID: 15381613 - Metastasectomy in malignant melanoma.
Karakousis CP, Velez A, Driscoll DL, Takita H. Karakousis CP, et al. Surgery. 1994 Mar;115(3):295-302. Surgery. 1994. PMID: 8128354 - [Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision].
Delaunay MM, Amici JM, Avril MF, Avril A, Barrut D, Blanc L, Blondet R, Bonichon E, Carolus JM, Depadt G, et al. Delaunay MM, et al. Ann Dermatol Venereol. 1991;118(4):287-95. Ann Dermatol Venereol. 1991. PMID: 2069340 Review. French. - Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
Pons F, Plana M, Caminal JM, Pera J, Fernandes I, Perez J, Garcia-Del-Muro X, Marcoval J, Penin R, Fabra A, Piulats JM. Pons F, et al. Melanoma Res. 2011 Jun;21(3):217-22. doi: 10.1097/CMR.0b013e3283457726. Melanoma Res. 2011. PMID: 21467954 Review.
Cited by
- Progressive Acral Lentiginous Melanoma diagnosed via histopathology and surgically eradicated in a fingernail in a 69-year-old male - A Case Report.
Ismael A, Alsamman MI, Al Laham O, Albrijawy R, Badran A. Ismael A, et al. Int J Surg Case Rep. 2022 Sep;98:107611. doi: 10.1016/j.ijscr.2022.107611. Epub 2022 Sep 7. Int J Surg Case Rep. 2022. PMID: 36380543 Free PMC article. - Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. DeConti RC, et al. Br J Cancer. 2010 Nov 9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5. Br J Cancer. 2010. PMID: 20924376 Free PMC article. Clinical Trial. - Epidemiology, management, and treatment outcomes of metastatic spinal melanoma.
Zheng DX, Soldozy S, Mulligan KM, Levoska MA, Cohn EF, Finberg A, Alsaloum P, Cwalina TB, Hanft SJ, Scott JF, Rothermel LD, Nambudiri VE. Zheng DX, et al. World Neurosurg X. 2023 Jan 21;18:100156. doi: 10.1016/j.wnsx.2023.100156. eCollection 2023 Apr. World Neurosurg X. 2023. PMID: 36875322 Free PMC article. Review. - Final version of 2009 AJCC melanoma staging and classification.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Balch CM, et al. J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16. J Clin Oncol. 2009. PMID: 19917835 Free PMC article. - Clinicopathologic Features and Prognostic Factors of Primary Cutaneous Melanoma: a Multicenter Study in Korea.
Kim JE, Chung BY, Sim CY, Park AY, Lee JS, Whang KU, Park YL, Kim HO, Park CW, Lee SY. Kim JE, et al. J Korean Med Sci. 2019 Apr 29;34(16):e126. doi: 10.3346/jkms.2019.34.e126. J Korean Med Sci. 2019. PMID: 31020815 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical